HealthTree Podcast for AML: Dr. Jane Liesveld, University of Rochester

The FLT3 gene mutation is the most common mutation seen in acute myeloid leukemia patients. It occurs in up to 37% of adult patients with AML. FLT3 mutations have been harder to treat with poor outcomes, however, with combination therapies using targeted drugs such as FLT3 inhibitors, outcomes have greatly improved. The development of FLT3 inhibitors has progressed in recent years and there are currently two FDA-approved options - gilteritinib and midostaurin. There are also many additional FLT3 inhibitors in development such as crenolanib and quizartinib, which leads us to the question of which FLT3 inhibitor should be used for each person and when is the appropriate time to add it to treatment?

Join us live on June 29th at 2 PM EST to hear from Dr. Jane Liesveld from the University of Rochester who will discuss the different FLT3 inhibitor options currently available, as well as the ones in development. She will also share research with us from a clinical trial she is leading comparing midostaurin and crenolanib when given following induction, consolidation and bone marrow transplantation.

During the show, Dr. Liesveld will discuss the differences between FLT3 inhibitor options and what has been learned from previous FLT3 inhibitor trials. Come learn all about the FLT3 mutation, FLT3 inhibitors and have the opportunity to directly ask Dr. Liesveld your questions.

Thank you to our episode sponsor, Abbvie.